

Wednesday 27/05/2021 at 3 pm

Points for discussion

1. Further development of COVID-19

What is the most likely scenario for the further development and continued spread of COVID-19?

How likely is the need for boosters and re-vaccinations?

What evidence exist on the duration of immunity? What is the evidence on heterologous boosters?

Aim: assess implications for the evolution of the vaccination strategy, to inform policymaking and communicate to the public.

2. Vaccination of teenagers and children and evolution of priority groups?

What are the arguments in favour of and against the vaccination of children and adolescents?

Should the priority groups be reviewed in the context of epidemiological developments, boosters and re-vaccinations?

3. Any other business